Am J Obstet Gynecol by Ellington, Sascha R. et al.
Recent trends in hepatic diseases during pregnancy in the 
United States, 2002–2010
Sascha R. Ellington, MSPH, Lisa Flowers, MPA, Jennifer K. Legardy-Williams, MPH, Denise 
J. Jamieson, MD, MPH, and Athena P. Kourtis, MD, PhD, MPH
Women’s Health and Fertility Branch, Division of Reproductive Health, National Center for 
Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 
Atlanta, GA
Abstract
OBJECTIVE—While pregnancy-related severe liver disorders are rare, when they occur 
morbidity and mortality rates are increased for mothers and infants. The objective of this study 
was to examine the prevalence and trends of hepatic diseases during pregnancy hospitalizations 
from 2002 through 2010 in the United States.
STUDY DESIGN—Hospital discharge data were obtained from the Nationwide Inpatient 
Sample, the largest all-payer hospital inpatient care database in the United States that provides 
nationally representative estimates. Pregnancy hospitalizations with the following diagnoses were 
identified: hepatitis B, hepatitis C, gallbladder disease/cholelithiasis, liver disorders of pregnancy, 
chronic/alcohol-related liver disease, biliary tract disease, and HELLP (hemolysis, elevated liver 
enzymes, low platelet count) syndrome. Age, insurance status, hospital location, and hospital 
region were compared among women with and without hepatic diseases using a χ2 test. Trends in 
rates of pregnancy hospitalizations and mean charges were analyzed using multivariable logistic 
and linear regression, respectively.
RESULTS—From 2002 through 2010 there were an estimated 41,479,358 pregnancy 
hospitalizations in the United States. Gallbladder disease and liver disorders of pregnancy were 
the most common hepatic diseases (rates = 7.18 and 4.65/1000 pregnancy hospitalizations, 
respectively). Adjusted rates and mean charges significantly increased for all hepatic diseases 
during pregnancy over the study period. All hepatic diseases were associated with significantly 
higher charges compared to all pregnancy hospitalizations. HELLP syndrome was associated with 
the highest mean charges.
CONCLUSION—This large study among a representative sample of the US population provides 
valuable information that can aid policy planning and management of these hepatic diseases 
during pregnancy in the United States.
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During pregnancy women may experience physiologic changes in their liver biochemical 
profile; however, pregnancy-related severe liver diseases are uncommon. When these 
complications occur, the morbidity and mortality rates are increased for the mother and 
fetus.1-4 Some liver diseases are unique to pregnancy, including acute fatty liver of 
pregnancy (AFLP), HELLP (hemolysis, elevated liver enzymes, low platelet count) 
syndrome, and intrahepatic cholestasis of pregnancy (ICP), all of which primarily occur in 
the third trimester. As previously documented, AFLP has affected between 1 in 7000 and 1 
in 20,000 pregnancies, and the maternal and fetal mortality rate is high.1,2,5 HELLP 
syndrome affects 0.5-0.9% of all pregnancies and 10-20% of severe preeclampsia cases6 and 
is associated with outcomes such as disseminated intravascular coagulopathy, placental 
abruption, acute renal failure, pulmonary edema, and cardiopulmonary arrest.5 Additionally, 
HELLP syndrome is associated with a fetal mortality of 7-20%.5 ICP affects approximately 
0.5-1% of pregnancies in the United States. Maternal complications from ICP are very rare, 
but fetal complications including prematurity, respiratory distress syndrome, and death can 
occur.1,5
In addition to liver diseases unique to pregnancy, other hepatic diseases such as viral 
hepatitis, biliary tract disease, and gallbladder disease create complications for mother and 
fetus during pregnancy. Approximately 1 million people are chronically infected with 
hepatitis B virus (HBV) in the United States.7 In 2005, approximately 24,000 chronically 
HBV-infected women gave birth in the United States.8 Hepatitis C virus (HCV) infection is 
the most common chronic blood-borne infection in the United States with approximately 3.9 
million people chronically infected.9,10 Among women of reproductive age in the United 
States, the prevalence of HCV infection is approximately 1%, with an estimated 40,000 
deliveries among HCV-infected women each year.11
Historically, the incidence of gallbladder and other biliary tract diseases during pregnancy 
has ranged from 0.05–0.3%.12-16 However, current estimates of incidence are lacking.1 
Among pregnant women, gallbladder disease is the second most common non-obstetrical 
indication for surgical intervention, as 5-12% of pregnant women have gall stones and the 
risk increases with gravidity.14
Cirrhosis is rare among pregnant women due in part to the low prevalence of cirrhosis in 
women of reproductive age (0.0004%). Additionally, most women with advanced cirrhosis 
have amenorrhea and anovulation.2,17,18 However, for women with cirrhosis who do 
become pregnant, the risk of maternal and fetal complications has been reported in up to 
50% of cases and maternal mortality has been reported in up to 10% of cases.2,19,20
There is little information about the prevalence of and trends in hepatic diseases in 
pregnancy in the United States. The Healthcare Cost and Utilization Project’s (HCUP) 
Nationwide Inpatient Sample (NIS) database provides a nationally representative sample of 
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US hospitalizations. The objective of this study was to examine the prevalence and trends of 
select hepatic diseases during pregnancy hospitalizations over 9 years in the United States.
Materials and Methods
We obtained hospital discharge data without identifiers from the HCUP NIS. The NIS, one 
of a family of research databases and software tools sponsored by the Agency for Healthcare 
Research and Quality in partnership with state-level data-collection organizations, provides 
research databases of national and regional inpatient care delivered in the United States.21
The NIS is a stratified probability sample of approximately 20% of all US community 
hospitals as defined by the American Hospital Association (AHA). Hospitals are selected for 
the NIS on the basis of 5 characteristics: geographic region, ownership, rural/urban location, 
teaching status, and bed size. The NIS includes all inpatient stays from an average of 
roughly 1000 hospitals; when weighted, the NIS data on 7 million discharges provide 
national estimates of inpatient care.22 It is the largest collection of inpatient care data in the 
United States and includes patient demographic data and diagnostic/procedural data, as well 
as facility information.
We analyzed NIS data for a 9-year period from 2002 through 2010, a period during which 
several revisions were made to the NIS design. The number of states in the NIS has 
increased from 35 in 2002 to 45 in 2010. This expanded the number of sampled hospitals 
from 995 in 2002 to 1051 in 2010. By 2010, these states included >96% of the US 
population. Beginning in 2004, NIS changed the classification of urban or rural hospital 
location for the sampling strata to use the newer Core Based Statistical Area codes, rather 
than the older Metropolitan Statistical Area codes. The Core Based Statistical Area groups 
are based on 2000 Census data, whereas the Metropolitan Statistical Area groups were based 
on 1990 Census data. Also, the criteria for classifying the counties differ.23 Before 2005, the 
AHA defined community hospitals as nonfederal, short-term (average length of stay <30 
days) general and specialty hospitals whose facilities are open to the public. Starting in 
2005, the AHA also included long-term acute-care facilities (stays of >25 days) in the 
definition of community hospitals, therefore such facilities are included in the NIS sampling 
frame.22
Our analysis was restricted to pregnant girls and women 15 years of age and older. We 
attempted to identify all pregnancy hospitalizations (excluding those for ectopic/molar 
pregnancy or spontaneous abortion) by searching for those with a primary or secondary 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
discharge code of 640-677, V22-V24, V27-V28, or 792.3. Pregnancy hospitalizations that 
resulted in a delivery were identified by ICD-9-CM codes 650 and V27, in addition to 
procedure codes of 720, 721, 722.1, 722.9, 723.1, 723.9, 724, 725.1-725.4, 726, 727.1, 
727.9, 728, 729, 732.2, 735.9, 736, 740-742, 744, and 749.9, and diagnosisrelated group 
codes of 370-375.
We examined all data in the following 3-year intervals: 2002 through 2004, 2005 through 
2007, and 2008 through 2010. We compared age distribution, insurance status, hospital 
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location, and hospital region for pregnant women with and without the following hepatic 
diseases: hepatitis B, hepatitis C, gallbladder disease/cholelithiasis, liver disorders of 
pregnancy, chronic and alcohol-related liver disease, biliary tract disease, and HELLP 
syndrome, using a χ2 test with a significance level of 0.0018 that adjusts for multiple 
corrections using a Bonferroni correction. Up to 25 diagnoses were examined for each 
pregnancy hospitalization. We used ICD-9-CM codes to identify pregnancy hospitalizations 
with these morbidities: (i) for HBV infection, ICD-9-CM codes 070.2, 070.3, 070.42, 
070.52; (ii) for HCV infection, ICD-9-CM codes 070.41, 070.44, 070.51, 070.54, 070.7; (iii) 
for other viral hepatitis including hepatitis A, hepatitis E, and unspecified viral hepatitis, 
ICD-9-CM codes 070.0, 070.1, 070.43, 070.49, 070.53, 070.59, 070.6, 070.9, 573.1, 573.2; 
(iv) for gallbladder disease/cholelithiasis, ICD-9-CM codes 574, 575; (v) for liver disorders 
of pregnancy including AFLP, ICP, icterus gravis pregnancy, necrosis of liver of pregnancy, 
and hepatorenal syndrome following delivery, ICD-9-CM codes 646.7, 674.8; (vi) for 
chronic and alcohol-related liver disease including cirrhosis, ICD-9-CM codes 571, 572; 
(vii) for other biliary tract diseases including cholangitis and obstruction, perforation, and 
fistula of the bile duct, ICD-9-CM code 576; and (viii) for hepatobiliary malignancies, 
ICD-9-CM codes 155.0, 155.1, 155.2, 156.0, 156.1, 156.2, 156.8, 156.9. There is no ICD-9-
CM code specifically for HELLP syndrome; rather it is typically coded as severe 
preeclampsia. We defined HELLP syndrome as severe preeclampsia (ICD-9-CM 642.5) 
with presence of at least one of the following: other disorders of the liver (ICD-9-CM codes 
570, 573.0, 573.3, 573.4, 573.8, 573.9), liver disorders of pregnancy (ICD-9-CM codes 
646.7, 674.8), or thrombocytopenia (ICD-9-CM codes 287.3, 287.4, 287.5).
Age was categorized as follows: 15-24 years, 25-34 years, and ≥35 years. Insurance status 
was dichotomized into private insurance and public/self–pay. Hospital location and hospital 
region were used as categorized in the NIS (location: rural, urban; region: Northeast, 
Midwest, South, West).
Trends in rates of pregnancy hospitalizations with a coded hepatic disease per 1000 
deliveries over time were compared using multivariable logistic regression models adjusted 
for age, insurance status, and delivery status, with 2002 through 2004 as the referent period. 
Additionally, to assess trends in mean hospital charges for pregnant women with hepatic 
diseases during pregnancy, we used linear regression adjusting for age, insurance status, and 
delivery status. Hospital charges were adjusted to account for inflation using the Bureau of 
Labor Statistics’ Consumer Price Index. Hospitalization-to-delivery ratios were calculated to 
assess disease burden during pregnancy. All statistical analyses were conducted with SAS 
callable SUDAAN, version 9.3 (Research Triangle Institute, NC).
The study was determined to be exempt from human subjects review as an analysis of 
preexisting deidentified data.
Results
From 2002 through 2010 there were an estimated 41,479,358 pregnancy hospitalizations 
including an estimated 37,465,214 deliveries available for the analysis. Table 1 shows the 
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crude rate in 3-year periods of hospitalizations in which a hepatic disease was coded per 
1000 pregnancy hospitalizations.
During the 9-year period, liver disorders of pregnancy and gallbladder disease were the most 
common hepatic diseases with rates of 7.18 and 4.65 per 1000 pregnancy hospitalizations, 
respectively (N = 192,940 and 297,653, respectively) (Table 1). Biliary tract disease and 
HELLP syndrome were less common with 69,346 (rate = 1.67/1000 pregnancy 
hospitalizations) and 39,365 (rate = 0.95/1000 pregnancy hospitalizations) total diagnoses, 
respectively. There were 39,664 pregnancy hospitalizations with a diagnosis of HBV (rate = 
0.96/1000 pregnancy hospitalizations) and 70,367 pregnancy hospitalizations with a 
diagnosis of HCV (rate = 1.70/1000 pregnancy hospitalizations) (Table 1). Diagnosis of 
other viral hepatitis during pregnancy was uncommon with 0.10 per 1000 pregnancy 
hospitalizations (N = 4075) and the rate remained unchanged over the study period (data not 
shown). Chronic and alcohol-related liver disease was rare with a rate of 0.30 per 1000 
pregnancy hospitalizations (N = 12,571) (Table 1).
Additionally, there were few hepatobiliary malignancies among pregnancy hospitalizations 
with only 90 (rate = 0.002/1000 pregnancy hospitalizations) diagnoses over the 9-year 
period (data not shown). No further analyses were conducted among pregnancy 
hospitalizations with a diagnosis of hepatobiliary malignancies or other viral hepatitis due to 
the rarity of the events.
The rates for all hepatic diseases during pregnancy reported in Table 1 increased over the 9-
year study period (Table 1). While rare, the rates of chronic and alcohol-related liver disease 
and biliary tract disease during pregnancy increased >100% from 2002 through 2004 to 
2008 through 2010 (Table 1).
Table 2 shows the distributions of patient age, insurance status, hospital location, and 
hospital region for each hepatic disease and all pregnancy hospitalizations. The distributions 
of these factors among all pregnancy hospitalizations are provided for reference, but were 
not used to calculate the χ2 P value. For each hepatic disease, comparisons were made 
between diseased and non-diseased hospitalizations.
The distributions of patient age, primary expected payer, and hospital region differed 
significantly between pregnancy hospitalizations with HBV or HCV and pregnancy 
hospitalizations without these diagnoses (Table 2). Compared with women without such a 
diagnosis, hospitalized pregnant women with an HBV or HCV diagnosis were older, less 
likely to have private insurance, and more likely to be in the Northeast and South regions of 
the United States. Additionally, disproportionately more pregnancy hospitalizations with 
HBV occurred among women in urban areas (Table 2).
Compared to pregnant women without a diagnosis of gallbladder disease, women with a 
diagnosis of gallbladder disease were disproportionately younger, less likely to have private 
insurance, more likely to be in a rural hospital, and more likely to be in the South and West 
regions of the United States (Table 2). Pregnant women with a diagnosis of liver disorders 
of pregnancy were older, less likely to have private insurance, more likely to be in an urban 
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hospital, and less likely to be in the Northeast region of the United States (Table 2) 
compared to pregnant women without such a diagnosis.
Pregnant women with a diagnosis of chronic and alcohol-related disease or biliary tract 
disease were disproportionately older, more likely to be in an urban hospital, and more 
likely to be in the Northeast and West regions of the United States compared to pregnant 
women without the respective diagnoses (Table 2). Pregnant women with a diagnosis of 
chronic and alcohol-related disease were also less likely to have private insurance. Pregnant 
women diagnosed with HELLP syndrome were older, more likely to be in an urban hospital, 
and more likely to be in the Southern region of the United States than were pregnant women 
who did not have a HELLP syndrome diagnosis (Table 2).
Compared to rates in 2002 through 2004, rates of pregnancy hospitalizations with hepatitis 
B did not change in 2005 through 2007, but did significantly increase by 17% during 2008 
through 2010 after adjusting for age, insurance status, and region. For hepatitis C, 
gallbladder disease, liver disorders of pregnancy, chronic and alcohol-related liver disease, 
biliary tract disease, and HELLP syndrome there were significant increases in the adjusted 
rates for 2005 through 2007 and 2008 through 2010 compared to the referent time period 
(2002 through 2004) (Table 3).
Charges are reported in 2010 dollars and are adjusted for age, insurance status, and delivery 
status. Mean charges significantly increased during 2005 through 2007 and 2008 through 
2010, compared to 2002 through 2004, for all pregnancy hospitalizations as well as those 
with a diagnosis of hepatitis C and gallbladder disease (Table 3). For all other outcomes, 
mean charges increased significantly only for the later period (2008 through 2010). All 
hepatic diseases were associated with significantly higher charges compared to all 
pregnancy hospitalizations (Table 3). Pregnant women with a diagnosis of HELLP 
syndrome had the highest mean charges at $30,129 per hospitalization during 2002 through 
2004, $33,118 in 2005 through 2007, and $34,921 in 2008 through 2010, approximately 3 
times the mean charges for all pregnancy hospitalizations in each time period.
In addition, Table 3 reports the ratio of the number of pregnancy hospitalizations with each 
hepatic disease to total number of deliveries, as well as the ratio for all pregnancy 
hospitalizations to number of deliveries. This ratio is a measure of the burden of serious 
pregnancy morbidity when a particular hepatic disease is present. The overall mean 
pregnancy hospitalization-to-delivery ratio showed a slight, but statistically significant, 
decrease in 2008 through 2010 compared to 2002 through 2004 (from 1.100-1.094), 
indicating a small overall decrease in the number of hospitalizations per pregnancy with 
time. Similarly, there was a significant but small decrease in the ratio of pregnancy 
hospitalizations to deliveries over time for pregnant women with a diagnosis of gallbladder 
disease. For all other hepatic outcomes there were no significant changes over time in the 
pregnancy hospitalization delivery ratio. The hospitalization-to-delivery ratio was highest 
for pregnancies with gallbladder disease and chronic and alcohol-related liver disease (Table 
3). The hospitalization-to-delivery ratio for women with a HELLP syndrome diagnosis was 
the lowest.
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Gallbladder disease and liver disorders of pregnancy were the most common hepatic 
diseases among those studied, a finding that is consistent with previous data.1,2,5,12-15 While 
gallbladder disease was more common in younger pregnant women, all other hepatic 
diseases were more common in older women, compared to all pregnancy hospitalizations. 
Diagnoses of all hepatic diseases but HELLP syndrome were more likely to be among 
women with public/self-pay vs private insurance. As with overall pregnancy 
hospitalizations, hepatic diseases were more common in urban areas. However, gallbladder 
disease was disproportionately represented in the rural hospitals. There were some 
differences in regional distribution of hepatic diseases as well.
Rates for all hepatic diseases during pregnancy increased significantly over the 3-year study 
intervals from 2002 through 2010. The number of overall pregnancy hospitalizations per 
delivery over time decreased slightly. Gallbladder disease followed a similar pattern, while 
no changes were observed in pregnancy hospitalization-to-delivery ratios for the other 
hepatic diseases studied.
Of the hepatic diseases studied, HELLP syndrome is the most costly per hospitalization, 
followed closely by chronic and alcohol-related liver disease. However, both diseases were 
rare and HELLP syndrome had the lowest hospitalization-to-delivery ratio since this 
condition typically occurs near or at the time of delivery. Given that pregnancies with a 
diagnosis of gallbladder disease and liver disorders of pregnancy were much more common 
and required more hospitalizations on average, gallbladder disease and liver disorders of 
pregnancy had a higher overall economic burden. Gallbladder disease had the highest 
burden of morbidity per pregnancy, as indicated by the highest pregnancy hospitalization-to-
delivery ratio observed among all outcomes (1.72 overall).
In our study, there were significantly more diagnoses of HBV and HCV found in pregnancy 
hospitalizations than in a similar study using HCUP NIS data from 1995 through 2005.3 
This is likely due to differences in ICD-9-CM codes used and not wholly contributable to 
increases in rates over time, particularly since we observed more cases from 2002 through 
2004 than previously observed in the 11-year period from 1995 through 2005.
There are several limitations in this study that are inherent to administrative data. ICD-9-CM 
coding may be influenced by many factors including reimbursement policies and temporal 
changes in practices, and has several imperfections, including grouping of several disorders 
into 1 category and lack of specific codes for others. For example, no specific code exists for 
AFLP or HELLP syndrome. AFLP is coded as a liver disorder of pregnancy while HELLP 
is coded as severe preeclampsia. The unit of measurement was the hospital admission, rather 
than the individual patient and patients may be represented more than once in a given year. 
In addition, hospitalizations usually capture more serious morbidities, and therefore may not 
provide a complete account of the morbidity burden of hepatic disease during pregnancy. 
Additionally, up to 25 ICD-9-CM codes were used to identify hepatic diseases, and therefore 
may not represent the true burden of disease since some of these may have been incidental 
findings from screening or discovered during the investigation of other conditions.
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Strengths of the study include its large sample size and the representativeness of the sample 
to the US population. Few recent studies have examined the prevalence of hepatic diseases 
among pregnant women from a nationally representative sample in the United States, and 
none in such a comprehensive manner that encompasses most categories of serious hepatic 
morbidities during pregnancy.
Clinical care of pregnant women with hepatic diseases can be challenging. There are 
physiologic changes in pregnancy that affect liver function that can affect diagnostic testing 
and clinical monitoring. Additionally, caring for pregnant women with preexisting liver 
disease, such as hepatitis B and C, is difficult to manage as effects of disease and treatment 
must balance fetal and maternal concerns. Pregnant women may be more susceptible to or 
have increased severity of certain liver diseases in pregnancy (eg, gallbladder disease/
cholelithiasis). These liver diseases and those that are unique to pregnancy such as HELLP 
syndrome, ICP, and AFLP can cause significant burden to the health care system due to the 
higher risk of complications for mothers and infants. Results of this analysis may aid health 
care policy planning by serving as a baseline for future studies of trends in prevalence as 
well as management of these conditions in the United States.
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TABLE 3
Trends in pregnancy hospitalizations with select hepatic diseases and related hospital charges: 2002 through 
2004, 2005 through 2007, and 2008 through 2010
Variable
Year
2002 through 2004 2005 through 2007 2008 through 2010
Hepatitis B
 Adjusted odds ratio (95% CI)a 1.00 1.10 (0.98-1.24) 1.17 (1.04-1.31)
 Mean charges (95% CI)b $11,833 ($10,889–12,777) $11,886 ($11,192–12,580) $15,509 ($14,099–16,920)
 Hospitalization-to-delivery ratio (95% CI)c 1.091 (1.075–1.106) 1.080 (1.067–1.093) 1.091 (1.077–1.106)
Hepatitis C
 Adjusted odds ratio (95% CI)a 1.00 1.28 (1.14–1.45) 1.55 (1.37–1.75)
 Mean charges (95% CI)b $12,768 ($11,817–13,720) $14,764 ($13,429–16,099) $16,255 ($15,081–17,429)
 Hospitalization-to-delivery ratio (95% CI)c 1.196 (1.179–1.213) 1.210 (1.190–1.230) 1.227 (1.207–1.248)
Gallbladder disease/cholelithiasis
 Adjusted odds ratio (95% CI)a 1.00 1.05 (1.00–1.09) 1.15 (1.10–1.20)
 Mean charges (95% CI)b $16,675 ($16,022–17,328) $18,250 ($17,655–18,844) $22,003 ($21,200–22,806)
 Hospitalization-to-delivery ratio (95% CI)c 1.735 (1.726–1.744) 1.721 (1.712–1.730) 1.704 (1.694–1.7146)
Liver disorders of pregnancy
 Adjusted odds ratio (95% CI)a 1.00 1.12 (1.04–1.21) 1.48 (1.36–1.61)
 Mean charges (95% CI)b $17,340 ($16,567–18,112) $18,141 ($17,476–18,806) $21,872 ($20,911–22,833)
 Hospitalization-to-delivery ratio (95% CI)c 1.295 (1.282–1.309) 1.289 (1.278–1.301) 1.280 (1.267–1.292)
Chronic and alcohol-related liver disease
 Adjusted odds ratio (95% CI)a 1.00 1.40 (1.23–1.60) 2.07 (1.82–2.35)
 Mean charges (95% CI)b $24,681 ($21,049–28,313) $31,285 ($25,016–37,555) $31,950 ($27,566–36,333)
 Hospitalization-to-delivery ratio (95% CI)c 1.411 (1.370–1.452) 1.407 (1.371–1.443) 1.441 (1.410–1.473)
Biliary tract disease
 Adjusted odds ratio (95% CI)a 1.00 1.47 (1.29–1.68) 2.25 (1.98–2.57)
 Mean charges (95% CI)b $15,875 ($14,314–17,436) $17,019 ($15,834–18,204) $19,726 ($18,430–21,022)
 Hospitalization-to-delivery ratio (95% CI)c 1.183 (1.166–1.200) 1.180 (1.1649–1.194) 1.156 (1.144–1.169)
HELLP syndrome
 Adjusted odds ratio (95% CI)a 1.00 1.09 (1.00–1.19) 1.52 (1.41–1.64)
 Mean charges (95% CI)b $30,129 ($27,810–32,449) $33,118 ($30,207–36,030) $34,921 ($32,559–37,284)
 Hospitalization-to-delivery ratio (95% CI)c 1.074 (1.063–1.0849) 1.072 (1.061–1.083) 1.074 (1.0645–1.084)
All pregnancy hospitalizations
 Mean charges (95% CI)b $9844 ($9501–10,188) $10,995 ($10,687–11,302) $12,910 ($12,496–13,325)
 Hospitalization-to-delivery ratio (95% CI)c 1.100 (1.097–1.102) 1.097 (1.0946–1.099) 1.094 (1.091–1.096)
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CI, confidence interval; HELLP, hemolysis, elevated liver enzymes, low platelet count.
a
Adjusted for age group, primary expected payer, and hospital region;
b
Standardized using 2010 Consumer Price Index, adjusted for age group, expected payer, and delivery status;
c
Ratio of number of hospitalizations with each outcome to total number of deliveries in same time period.
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